Hair density and regrowth — peptide, drug, procedure, and lifestyle options compared

Hair density complaints span a wider clinical landscape than most adopters realize. Androgenetic alopecia (male pattern baldness, female pattern hair loss) is the most common driver and has substantial evidence-based intervention options. But a meaningful fraction of hair-loss complaints are telogen effluvium (stress-induced shedding), nutritional (iron, vitamin D, thyroid), traction-related, autoimmune (alopecia areata, scarring alopecias), or post-pharmacological (post-finasteride, post-chemotherapy). The right intervention depends entirely on which is operating.

This guide compares the realistic options for the most common case: androgenetic alopecia in adults seeking density preservation or modest regrowth. The harm-reduction frame: the highest-evidence-base interventions are unsexy (minoxidil, finasteride, structured workup), the moderately-evidenced interventions are increasingly accessible (microneedling, dutasteride, oral minoxidil), and the peptide options sit in a narrow niche where the evidence is interesting but modest in absolute terms.

The load-bearing observation: for androgenetic alopecia, the highest-leverage interventions are pharmacological (DHT-modulating + minoxidil), not peptide-based, not procedural, not lifestyle. The peptide options in this category are at best adjuncts. This is the goal area where the peptide story is weakest relative to the alternatives.

The comparison

Option	Evidence tier (for AGA)	Effect type	Time to outcome	Cost / month (US, 2026 est.)	Side effects	Reversibility	Who should consider	Who should skip
Workup for treatable causes (iron, vitamin D, thyroid, scalp dermatology)	Tier 1	Treats actual cause	Variable	$200-500 one-time	None	Per-intervention	Anyone with new-onset hair loss; women with hair density change	Anyone who hasn't been worked up — workup is non-optional
Minoxidil topical (5% men, 2% women)	Tier 1 (FDA-approved; decades of data)	Increases anagen phase; vellus → terminal hair conversion	16-24 weeks	$10-30 generic	Scalp irritation, shedding phase weeks 2-8, optional facial hair growth	Reverses to original trajectory on stop within 3-6 months	Most users with AGA seeking density preservation	Severe scalp dermatitis; pregnancy (women)
Minoxidil oral (low-dose, 0.5-5 mg)	Tier 2 (off-label; growing evidence)	Systemic vasodilation effect on hair follicles	16-24 weeks	$15-40 with prescription	Hirsutism (women), pedal edema, palpitations, BP drop	Reverses on stop	Topical non-responders; users who prefer once-daily oral	Cardiovascular comorbidity; uncontrolled hypertension; women trying to conceive
Finasteride (1 mg oral) — men	Tier 1 (FDA-approved AGA; large RCT base)	5α-reductase II inhibition; reduces DHT ~70%	16-26 weeks	$10-40 generic	Sexual side effects ~3-15%; "post-finasteride syndrome" rare but documented; mood changes; gynecomastia rare	Reverses on stop; some persistent reports	Men with AGA willing to commit to ongoing therapy	Women of childbearing potential; men with significant pre-existing sexual dysfunction; mood-disorder history
Dutasteride (0.5 mg)	Tier 1 (approved in some markets for AGA; off-label in US)	5α-reductase I+II inhibition; reduces DHT ~90%	16-26 weeks	$30-100	Same class as finasteride; potentially more pronounced; longer washout	Reverses slowly (months) due to long half-life	Finasteride non-responders or those wanting stronger effect	Same as finasteride; harder to discontinue cleanly
Spironolactone (women, off-label)	Tier 2 for AGA in women	Anti-androgen	16-26 weeks	$10-30	Diuresis, electrolyte changes, menstrual irregularity, breast tenderness	Reverses on stop	Female pattern hair loss; PCOS-pattern hair loss	Hyperkalemia risk; pregnancy
Microneedling (in-office or home)	Tier 2 (positive small-to-medium RCT evidence)	Mechanical stimulation; promotes anagen; minoxidil penetration if combined	16-24 weeks	$30-120 home (Dermaroller / Dermapen); $300-800/session in-office	Transient erythema, occasional scarring if improperly done	Effect builds with sustained practice	Adjunct to minoxidil; users wanting non-pharmacological supplement	Sensitive scalp; bleeding disorders; isotretinoin within 6 months
PRP (platelet-rich plasma) injection	Tier 2 (mixed RCT evidence; positive direction in most)	Growth factor injection into scalp	16-26 weeks; 3-4 sessions	$500-1500 per session; usually 3-4 sessions	Injection-site pain, transient flare	Effect maintained ~3-6 months; repeat sessions needed	Topical-treatment non-responders with budget; AGA + concomitant hair-system fitting	Severe coagulation disorders; budget-constrained users
Low-level laser therapy (LLLT) / red light	Tier 2-3	Photobiomodulation	16-26 weeks	$200-600 one-time device; some clinic-based	None significant	Effect maintained with continued use	Adjunct to other therapies; users wanting at-home option	Anyone expecting standalone results
GHK-Cu (topical scalp)	Tier 2-3 (small-cohort evidence; replicated direction; mechanistic plausibility)	Stimulates fibroblast collagen + ECM; possible anagen promotion; established cosmetic adoption	12-24 weeks	$30-100 (compounded or research-supplier)	Topical irritation (rare); blue staining of pillow / clothing	Reverses on stop	AGA adjunct to minoxidil (often stacked); users wanting cosmetic skin-quality + hair effect	Standalone replacement for first-line therapy; rapid-progression hair loss
Hair transplantation (FUE / FUT)	Tier 1 for established cases	Surgical redistribution of follicles	6-12 months for visible result; permanent	$5,000-15,000 one-time	Surgical risk; donor-area thinning; "shock loss" phase	Permanent for transplanted follicles; ongoing AGA still progresses elsewhere	AGA with stable miniaturization pattern + adequate donor; budget	Active rapid progression; insufficient donor area; expectations of full restoration
Choosing acceptance	Tier 1 in honesty	None	Immediate	$0	None	None	Anyone for whom continued intervention isn't worth the trade-offs	Anyone with autoimmune or scarring pattern (workup non-optional)

The top six rows handle the substantive evidence base for AGA. Peptides (GHK-Cu) sit as a Tier 2-3 adjunct, not a primary treatment. Hair transplantation is the gold standard for visible regrowth but is surgical and expensive. The "acceptance" row matters more than the marketing acknowledges.

This guide carries the public comparison. The member continuation walks the per-option evidence in depth, the GHK-Cu specific case, the differential workup framework, and the founder's view.